Search results
Showing 466 to 480 of 1044 results for criteria
Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making
Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for treating advanced (unresectable or metastatic) melanoma in adults.
Evidence-based recommendations on 2 adjunctive colposcopy technologies (the DYSIS colposcope with DYSISmap and the ZedScan I) for assessing suspected cervical abnormalities in people having colposcopy
Find out how we assess the value of digital health technologies and help developers build the evidence needed to achieve market access and improve lives.
This guideline covers management of acne vulgaris in primary and specialist care. It includes advice on topical and oral treatments (including antibiotics and retinoids), treatment using physical modalities, and the impact of acne vulgaris on mental health and wellbeing.
The Juxta CURES adjustable compression system for treating venous leg ulcers (MIB25)
NICE has developed a medtech innovation briefing (MIB) on the Juxta CURES adjustable compression system for treating venous leg ulcers
LARS for reconstructing damaged intra-articular cruciate knee ligaments (MIB30)
NICE has developed a medtech innovation briefing (MIB) on LARS for reconstructing damaged intra-articular cruciate knee ligaments
This quality standard covers diagnosing and managing stable angina in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS21Show all sections
Sections for QS21
- Quality statements
- Quality statement 1: Diagnostic investigation
- Quality statement 2: First-line treatment
- Quality statement 3: Medical treatment before revascularisation
- Quality statement 4: Multidisciplinary team
- Quality statement 5: Symptoms not responding to treatment
- Update information
- About this quality standard
NICE has developed a medtech innovation briefing (MIB) on SYNE-COV for predicting COVID-19 outcomes .
Micropressure therapy for refractory Ménière's disease (IPG426)
Evidence-based recommendations on micropressure therapy for refractory Ménière's disease. This involves inserting a grommet (small tube) through the eardrum into the middle ear and blowing air at low pressure into the inner ear.
View recommendations for IPG426Show all sections
Sections for IPG426
Acalabrutinib for treating chronic lymphocytic leukaemia (TA689)
Evidence-based recommendations on acalabrutinib (Calquence) for treating chronic lymphocytic leukaemia in adults.
Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy in adults.
Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)
Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.
Ustekinumab for the treatment of adults with moderate to severe psoriasis (TA180)
Evidence-based recommendations on ustekinumab (Stelara) for treating psoriasis in adults.